Compare NEON & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | BCDA |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 14.1M |
| IPO Year | 1994 | 2009 |
| Metric | NEON | BCDA |
|---|---|---|
| Price | $0.95 | $2.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $25.00 |
| AVG Volume (30 Days) | 98.8K | ★ 230.2K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,108,000.00 | $479,000.00 |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.75 |
| 52 Week High | $25.90 | $2.29 |
| Indicator | NEON | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.26 |
| Support Level | N/A | $0.80 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 99.95 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).